{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T05:43:01Z","timestamp":1773207781803,"version":"3.50.1"},"reference-count":29,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2017,7,2]],"date-time":"2017-07-02T00:00:00Z","timestamp":1498953600000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      To develop a tool to predict the need for pharmacologic treatment of neonatal abstinence syndrome (\n                      <jats:styled-content style=\"fixed-case\">NAS<\/jats:styled-content>\n                      ) within 36 hours from birth in infants at risk for opioid withdrawal.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Design<\/jats:title>\n                    <jats:p>\n                      Retrospective study of infants born at gestation of \u226534 weeks with in utero exposure to opioids during two time periods from January 2013 through October 2016. Period 1 was used to develop a predictive tool for validation during period 2. Birth weight, gestational age, four categories of opioid exposure, and individual scores for 21 withdrawal symptoms from the Modified Finnegan Score at 36 hours of life were recorded. During period 1, a best subsets multiple regression analysis was performed on factors that were associated with pharmacotherapy on univariate analysis. Two tools were designed: one based on three highly predictive symptoms associated with need for pharmacotherapy for\n                      <jats:styled-content style=\"fixed-case\">NAS<\/jats:styled-content>\n                      and the other incorporating opioid exposure. Sensitivity, specificity, and positive and negative predictive values for the tools were calculated during period 2.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The study included 264 infants (period 1, n=143; period 2, n=121). Polysubstance exposure and three withdrawal symptoms present at 36 hours of life that were significantly associated with pharmacotherapy for\n                      <jats:styled-content style=\"fixed-case\">NAS<\/jats:styled-content>\n                      comprised the tools. The \u201csymptoms only tool\u201d was able to predict that infants with a score &lt;1 would not receive pharmacotherapy, and infants with scores of \u22654 would receive pharmacotherapy with positive predictive values of 90% and 100%, respectively. When opioid exposure was included, the \u201csymptoms + exposure tool\u201d was able to predict that infants with a score of \u22641 would not receive pharmacotherapy and infants with scores of \u22655 would receive pharmacotherapy with positive predictive values of 94% and 86%, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      An\n                      <jats:styled-content style=\"fixed-case\">NAS<\/jats:styled-content>\n                      prediction tool combining three clinical signs with and without category of opioid exposure had high positive predictive values for requiring and for not requiring pharmacotherapy. This tool may expedite pharmacotherapy decisions and optimize management for infants at risk for\n                      <jats:styled-content style=\"fixed-case\">NAS<\/jats:styled-content>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/phar.1948","type":"journal-article","created":{"date-parts":[[2017,5,13]],"date-time":"2017-05-13T04:47:18Z","timestamp":1494650838000},"page":"840-848","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Early Prediction Tool to Identify the Need for Pharmacotherapy in Infants at Risk of Neonatal Abstinence Syndrome"],"prefix":"10.1002","volume":"37","author":[{"given":"Barbara T.","family":"Isemann","sequence":"first","affiliation":[{"name":"Department of Pharmacy University of Cincinnati Medical Center Cincinnati Ohio"},{"name":"James L. Winkle College of Pharmacy University of Cincinnati Cincinnati Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elaina C.","family":"Stoeckle","sequence":"additional","affiliation":[{"name":"James L. Winkle College of Pharmacy University of Cincinnati Cincinnati Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Afshin A.","family":"Taleghani","sequence":"additional","affiliation":[{"name":"Department of Pharmacy University of Cincinnati Medical Center Cincinnati Ohio"},{"name":"James L. Winkle College of Pharmacy University of Cincinnati Cincinnati Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric W.","family":"Mueller","sequence":"additional","affiliation":[{"name":"Department of Pharmacy University of Cincinnati Medical Center Cincinnati Ohio"},{"name":"James L. Winkle College of Pharmacy University of Cincinnati Cincinnati Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,7,2]]},"reference":[{"key":"e_1_2_7_2_1","first-page":"1487","article-title":"Vital signs: overdoses of prescription opioid pain relievers\u2014United States, 1999\u20132008","volume":"60","author":"Centers for Disease Control and Prevention (CDC)","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.3951"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/jp.2015.36"},{"key":"e_1_2_7_5_1","volume-title":"Results from the 2013 national survey on drug use and health: summary of national findings, NSDUH series H\u201048, HHS publication No. (SMA) 14\u20104863","author":"Substance Abuse and Mental Health Services Administration","year":"2014"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e318256496e"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.whi.2010.02.003"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000466371.86393.9b"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa1500439"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2014-3299"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/jp.2010.66"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.1224"},{"key":"e_1_2_7_13_1","first-page":"80","article-title":"Prospective randomized comparative study of the effect of buprenorphine, methadone and heroin on the course of pregnancy, birthweight of newborns, early postpartum adaptation and course of the neonatal abstinence syndrome (NAS) in women followed up in the outpatient department","volume":"29","author":"Binder T","year":"2008","journal-title":"Neuro Endocrinol Lett"},{"key":"e_1_2_7_14_1","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1515\/jpm-2012-0288","article-title":"Are there gender related differences in neonatal abstinence syndrome following exposure to buprenorphine during pregnancy?","volume":"41","author":"O'Connor AB","year":"2013","journal-title":"J Perinat Med"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1005359"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwu190"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2013-4036"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-3835"},{"issue":"1","key":"e_1_2_7_19_1","first-page":"141","article-title":"Neonatal abstinence syndrome: assessment and management","volume":"2","author":"Finnegan LP","year":"1975","journal-title":"Addict Dis"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2011-3212"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2012.04038.x"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(76)81074-8"},{"key":"e_1_2_7_23_1","article-title":"Can methadone concentrations predict the severity of withdrawal in infants at risk of neonatal abstinence syndrome?","volume":"390","author":"Kuschel CA","year":"2003","journal-title":"Arch Dis Child"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2015.11.039"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/ANC.0b013e318241bd73"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/000992287501400613"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2008.06.088"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0029-7844(02)02387-6"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2013.06.004"},{"key":"e_1_2_7_30_1","unstructured":"Association of State and Territorial Health Officials (ASTHO).How state health departments can use the spectrum of prevention to address neonatal abstinence syndrome. Companion Report. Arlington VA: ASTHO; 2015. Available fromhttp:\/\/www.astho.org\/Prevention\/Rx\/NAS-Framework. Accessed December 7 2016."}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1948","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.1948","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:35:29Z","timestamp":1761068129000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.1948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["10.1002\/phar.1948"],"URL":"https:\/\/doi.org\/10.1002\/phar.1948","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"2017-07-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}